Genetically engineered bacterium for producing ganoderic acid DM as well as construction method and application thereof
By constructing recombinant yeast cells expressing specific genes in Saccharomyces cerevisiae and optimizing the precursor synthesis pathway, the yield of Ganoderma DM was successfully improved, the problem of low Ganoderma DM content in the existing technology was solved, and the efficiency of Ganoderma DM was achieved Heterologous synthesis.
Patent Information
- Application Number
- CN202411182192.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-27
Smart Images

Figure CN118909817A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and relates to a genetic engineering bacterium producing ganoderic acid DM and a construction method and application thereof. Background Art
[0002] Lingzhi is a precious medicinal fungus that has been used as a herbal medicine in traditional Chinese medicine for more than 2,000 years. Lingzhi has significant effects in the treatment and prevention of various diseases, such as anti-tumor, anti-liver fibrosis, relief of hyperglycemia, lipid-lowering and anti-atherosclerosis. In addition, Lingzhi is also widely used in the nutritional health care and cosmetics industries. With the development of biotechnology, many researchers have conducted in-depth research on the bioactive components of Lingzhi and Lingzhi-derived products, and found that the main substances are terpenes, polysaccharides, sterols, etc.
[0003] Ganoderic acid, a triterpenoid compound, is a major active ingredient in Ganoderma lucidum. Studies have shown that ganoderic acid plays an important role in anti-tumor, anti-aging, anti-inflammatory, anti-depression, anti-epileptic, and Alzheimer's disease treatment. Ganoderic acid is diverse and complex in structure, and many ganoderic acids have entered preclinical or clinical studies in the process of drug development. Ganoderic acid A and its amide derivatives inhibit various types of tumor cells by regulating the p53-MDM2 pathway. Ganoderic acid A also enhances the tumor suppression function of oxaliplatin by inducing T cell cytotoxicity. Ganoderic acid DM (GA-DM) can induce autophagic apoptosis in non-small cell lung cancer cells by inhibiting Akt / mTOR activity; in addition, GA-DM shows minimal toxicity to other normal cells while inducing cancer cell death. Published studies have shown that the use of GA-DM as an alternative or complementary treatment against advanced cancer in cancer treatment has broad prospects.
[0004] The main way to obtain ganoderic acid is to extract it from the fruiting bodies and spores of Ganoderma lucidum. However, wild Ganoderma lucidum resources are scarce and expensive, and the product quality of artificially cultivated Ganoderma lucidum is uneven and the productivity is low. In recent years, researchers have used the technology of deep fermentation of Ganoderma lucidum mycelium to extract ganoderic acid. Although it has the advantages of saving time, labor, energy and environmental protection, the low content of ganoderic acid in Ganoderma lucidum fermentation cannot achieve large-scale production of ganoderic acid monomers, which limits the clinical application of ganoderic acid including GA-DM. Therefore, analyzing the biosynthetic pathway of ganoderic acid is of great significance for increasing the content of ganoderic acid. At the same time, the use of synthetic biology methods to transform industrial microorganisms to synthesize ganoderic acid can solve the above problems.
[0005] Studies have shown that the biosynthesis of ganoderic acid is based on acetyl-CoA as a precursor and then synthesized through the mevalonate pathway (MVA). First, three molecules of acetyl-CoA undergo two condensations to form 3-hydroxy-3-methyl-glutaryl-CoA, and then mevalonate is generated under the action of 3-hydroxy-3-methyl-glutaryl-CoA reductase. Then, isopenteyl-pyrophsphate (IPP) is generated under the continuous action of methylvalerate kinase, mevalonate-5-phosphate kinase and pyrophosphate mevalonate decarboxylase. IPP can be isomerized to dimethylallyl diphosphate (DMAPP) under the activation of isopentenyl diphosphate isomerase (IDI). Two molecules of IPP and one molecule of DMAPP condense head-to-tail to form farnesyl diphosphate (FPP) under the catalysis of farnesyl phosphate synthase. FPP is converted into squalene under the catalysis of squalene synthase, and then lanosterol is generated under the catalysis of lanosterol synthase. However, it is still unclear what reactions lanosterol undergoes to finally synthesize ganoderic acid; in fact, the existing technology has not yet analyzed most of the enzymes required for the biosynthesis of ganoderic acid, and only a small amount of ganoderic acid synthase has been identified. At present, the low content and large variety of ganoderic acid may lead to slow progress in the identification of key enzymes for ganoderic acid biosynthesis, so the heterologous biosynthesis of most ganoderic acids cannot be achieved. Summary of the invention
[0006] One of the purposes of the present invention is to provide a genetically engineered bacterium for producing ganoderic acid DM in view of the above-mentioned deficiencies in the prior art, wherein the genetically engineered bacterium can realize heterologous synthesis of ganoderic acid and can efficiently synthesize ganoderic acid DM.
[0007] The second purpose of the present invention is to provide a method for constructing a genetically engineered bacterium that produces ganoderic acid DM, which method can break through the current limitations of the knowledge of ganoderic acid biosynthetic enzymes and achieve heterologous synthesis of ganoderic acid.
[0008] The third object of the present invention is to provide an application of a genetically engineered bacterium that produces ganoderic acid DM, so as to achieve heterologous and efficient production of ganoderic acid DM.
[0009] To this end, the first aspect of the present invention provides a genetically engineered bacterium that produces ganoderic acid DM, which is a recombinant yeast cell that expresses exogenous CYP5150L8 gene encoding CYP450 enzyme, CYP7A1 gene encoding 7α-hydroxylase, HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase, and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase.
[0010] In some embodiments of the present invention, the CYP5150L8 gene includes a codon-optimized CYP5150L8 gene encoding a CYP450 enzyme derived from Ganoderma lucidum; preferably, the nucleotide sequence of the CYP5150L8 gene is as shown in SEQ ID NO.1.
[0011] In some embodiments of the present invention, the CYP7A1 gene includes a codon-optimized CYP7A1 gene encoding 7α-hydroxylase derived from Homo sapiens; preferably, the nucleotide sequence of the CYP7A1 gene is shown in SEQ ID NO.2.
[0012] In some embodiments of the present invention, the HSD3B7 gene includes a codon-optimized HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase derived from Homo sapiens; preferably, the nucleotide sequence of the HSD3B7 gene is shown in SEQ ID NO.3.
[0013] In some embodiments of the present invention, the 7α-HSDH gene includes a codon-optimized 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase derived from Clostridium sardiniense; preferably, the nucleotide sequence of the 7α-HSDH gene is as shown in SEQ ID NO.4.
[0014] In the present invention, the expression method is plasmid expression or genome integration expression.
[0015] According to the present invention, the genetically engineered bacteria are genetically engineered bacteria that have undergone chassis modification; the chassis modification includes optimization of the precursor synthesis pathway.
[0016] Preferably, the optimization of the precursor synthesis pathway includes overexpressing one or more of the endogenous tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene in recombinant yeast cells.
[0017] In some specific embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in recombinant yeast cells.
[0018] In some specific embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase in recombinant yeast cells.
[0019] In some specific embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase and the ERG20 gene encoding farnesyl pyrophosphate synthase in recombinant yeast cells.
[0020] In some specific embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase and the ERG12 gene encoding mevalonate kinase in recombinant yeast cells.
[0021] In some specific embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the transcription activator UPC2 gene in recombinant yeast cells.
[0022] In the present invention, the yeast cell is selected from the group consisting of the following yeast cells: Yarrowia lipolytica, Rhodosporidium, Lipomyces, Lipomyces oleaginus, Rhodotorula glutinosus, Cryptococcus curvatus, Candida curvatus, Trichosporon fermentans, Candida lakovii, Rhodopsinum ferrugineum, Candida tropicalis, Candida utilis, Trichosporon dermestii and Saccharomyces cerevisiae, preferably Saccharomyces cerevisiae.
[0023] The second aspect of the present invention provides a method for constructing a genetically engineered bacterium as described in the first aspect of the present invention, comprising: a step of constructing a recombinant yeast cell A: using yeast cells as a chassis strain to express exogenous CYP5150L8 gene encoding CYP450 enzyme, CYP7A1 gene encoding 7α-hydroxylase, HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase to obtain recombinant yeast cell A.
[0024] According to the present invention, the construction method further comprises a step of optimizing the precursor synthesis pathway after the step of constructing the recombinant yeast cell A, which comprises:
[0025] Overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in recombinant yeast cell A to obtain recombinant yeast cell B;
[0026] Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell C;
[0027] Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell D;
[0028] Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell E;
[0029] Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene are overexpressed in recombinant yeast cells to obtain recombinant yeast cells F.
[0030] The third aspect of the present invention provides the use of the genetically engineered bacteria as described in the first aspect of the present invention or the genetically engineered bacteria constructed by the construction method as described in the second aspect of the present invention in the production of ganoderic acid DM.
[0031] In some embodiments of the present invention, the application includes inoculating the genetically engineered bacteria into a fermentation medium for fermentation culture, and then separating and purifying the obtained fermentation culture fluid to obtain ganoderic acid DM.
[0032] Preferably, the fermentation medium comprises one or more of YPD fermentation medium, YNB-Ura / Leu fermentation medium and YNB-Ura / Leu / Trp fermentation medium;
[0033] More preferably, the fermentation temperature is 30°C; and even more preferably, the fermentation time is 168h.
[0034] The beneficial effects of the present invention are mainly reflected in: the present invention realizes the production of ganoderic acid DM in saccharomyces cerevisiae for the first time, breaks through the limitation of the source of ganoderic acid DM, and provides a new method for realizing the heterologous synthesis of ganoderic acid. The present invention expresses the CYP5150L8-CYP7A1-HSD3B7-7α-HSDH gene and overexpresses the tHMG1 and / or IDI1 and / or ERG20 and / or ERG12 and / or UPC2 genes in the saccharomyces cerevisiae strain YS58, constructs a genetically engineered saccharomyces cerevisiae, effectively increases the content of ganoderic acid DM in the saccharomyces cerevisiae, and makes the ganoderic acid DM production of the genetically engineered saccharomyces cerevisiae reach 118 mg / L. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The present invention will be further described in detail below in conjunction with the accompanying drawings:
[0036] Figure 1 The biosynthetic pathway of ganoderic acid DM in the recombinant Saccharomyces cerevisiae cells provided by the present invention is shown.
[0037] Figure 2 It was shown that the expression of CYP5150L8-CYP7A1-HSD3B7-7α-HSDH gene produced ganoderic acid DM in Saccharomyces cerevisiae.
[0038] Figure 3 The effects of overexpression of the tHMG1 gene, coexpression of the tHMG1 gene and the IDI1 gene, coexpression of the tHMG1 gene, the IDI1 gene and the ERG20 gene, coexpression of the tHMG1 gene, the IDI1 gene, the ERG20 gene and the ERG12 gene, or coexpression of the tHMG1 gene, the IDI1 gene, the ERG20 gene, the ERG12 gene and the UPC2 gene on the production of ganoderic acid DM by the engineered bacteria are shown. DETAILED DESCRIPTION
[0039] To make the present invention easy to understand, the present invention will be described in detail below in conjunction with the accompanying drawings. However, before describing the present invention in detail, it should be understood that the present invention is not limited to the specific embodiments described. It should also be understood that the terms used herein are only for describing specific embodiments and are not intended to be limiting.
[0040] Unless otherwise defined, all terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, preferred methods and materials are now described.
[0041] I. Terminology
[0042] The term "gene recombination cassette" in the present invention refers to a foreign gene fragment transformed into yeast cells and capable of integrating into the yeast genome, including an upstream homology arm, a promoter, a gene, a terminator, a screening gene, and a downstream homology arm.
[0043] II. Implementation Plan
[0044] As mentioned above, ganoderic acid is biosynthesized through the MVA pathway using acetyl-CoA as a precursor. However, it is not clear what reactions lanosterol undergoes to ultimately synthesize ganoderic acid; in fact, the prior art has not yet resolved most of the enzymes required for ganoderic acid biosynthesis, and only identified a small amount of ganoderic acid synthase. At present, the low content and large variety of ganoderic acid may lead to slow progress in the identification of key enzymes in ganoderic acid biosynthesis. In view of this, the inventors have conducted a lot of in-depth research on the ganoderic acid biosynthesis pathway.
[0045] After research, the inventors speculated that the cytochrome P450 superfamily (CYP) plays an important role in the modification of the lanosterol skeleton; based on this, the inventors further studied and designed and found that using yeast cells as expression hosts, expressing CYP450 gene CYP5150L8, 7α-hydroxylase encoding gene CYP7A1, 3β-hydroxysteroid dehydrogenase encoding gene HSD3B7 and 7α-hydroxysteroid dehydrogenase encoding gene 7α-HSDH and overexpressing tHMG1 gene encoding hydroxymethylglutaryl coenzyme A reductase and / or IDI1 gene encoding isopentenyl diphosphate δ-isomerase and / or ERG20 gene encoding farnesyl pyrophosphate synthase and / or ERG12 gene encoding mevalonate kinase and / or transcription activator UPC2 gene, constructing a genetically engineered yeast of cerevisiae, it is possible to successfully produce ganoderic acid DM in cerevisiae, thereby constructing a genetically engineered bacterium that efficiently produces ganoderic acid DM, and thus obtaining the present invention.
[0046] Therefore, the genetically engineered bacteria producing ganoderic acid DM provided by the present invention are constructed by using Saccharomyces cerevisiae as an expression host; the yeast cell is selected from the group consisting of the following yeast cells: Yarrowia lipolytica, red winter spore yeast, lipogenic yeast, oleaginous yeast, viscous red yeast, Cryptococcus curvatus, Candida curvatus, Trichosporon fermentans, Candida lakovii, red Candida ferrugineus, Candida tropicalis, Candida utilis, Trichosporon dermoides and Saccharomyces cerevisiae, preferably Saccharomyces cerevisiae; for example, in some preferred examples, the present invention uses Saccharomyces cerevisiae YS58 (strain collection number is ST12300, purchased from Beijing Cresbo Biotechnology Co., Ltd.) as the expression host.
[0047] In an embodiment of the present invention, the genetically engineered bacteria producing ganoderic acid DM are recombinant yeast cells containing exogenous CYP5150L8 gene encoding CYP450 enzyme (referred to as CYP5150L8 gene), CYP7A1 gene encoding 7α-hydroxylase (referred to as CYP7A1 gene), HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase (referred to as HSD3B7 gene) and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase (referred to as 7α-HSDH gene), which are also referred to as initial genetically engineered bacteria producing ganoderic acid DM or initial recombinant yeast cells producing ganoderic acid DM in the present invention.
[0048] Those skilled in the art should understand that the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase are genes not present in the chassis strain used (i.e., the host cell, Saccharomyces cerevisiae); in the present invention, the CYP5150L8 gene is derived from Ganoderma lucidum, the CYP7A1 gene encoding the 7α-hydroxylase is derived from Homo sapiens, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase is derived from Homo sapiens, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase is derived from Clostridium sardiniense, and the above genes are expressed in genetically engineered bacteria.
[0049] Preferably, the above genes are all codon-optimized and co-expressed in genetically engineered bacteria; specifically, the nucleotide sequence of the CYP5150L8 gene derived from Ganoderma lucidum and codon-optimized is shown in SEQ ID No. 1, the nucleotide sequence of the CYP7A1 gene encoding 7α-hydroxylase derived from Homo sapiens and codon-optimized is shown in SEQ ID No. 2, the nucleotide sequence of the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase derived from Homo sapiens and codon-optimized is shown in SEQ ID No. 3, and the nucleotide sequence of the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase derived from Clostridium sardiniense and codon-optimized is shown in SEQ ID No. 4.
[0050] In some preferred embodiments of the present invention, the genetically engineered bacteria express the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase, and produce ganoderic acid DM in Saccharomyces cerevisiae; in the present invention, the corresponding recombinant Saccharomyces cerevisiae cell is referred to as the recombinant yeast cell A producing ganoderic acid DM, and its biosynthetic pathway is as follows: Figure 1 shown.
[0051] In order to improve the ganoderic acid DM production capacity of the initial recombinant yeast, in some preferred embodiments of the present invention, the precursor synthesis pathway of the obtained initial recombinant yeast cells producing ganoderic acid DM is optimized to obtain recombinant yeast cells with optimized precursor synthesis pathway, which are also referred to as recombinant yeast cells producing ganoderic acid DM with optimized precursor synthesis pathway in the present invention.
[0052] Preferably, in the present invention, the precursor synthesis pathway is optimized by overexpressing one or more of the following genes: tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, IDI1 gene encoding isopentenyl diphosphate δ-isomerase, ERG20 gene encoding farnesyl pyrophosphate synthase, ERG12 gene encoding mevalonate kinase, and endogenous transcription activator UPC2 gene in recombinant yeast cells.
[0053] In the present invention, the nucleotide sequence of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase is shown in positions 1045-2580 of SEQ ID No.5; the nucleotide sequence of the IDI1 gene encoding isopentenyl diphosphate δ-isomerase is shown in positions 1045-1911 of SEQ ID No.6; and the nucleotide sequence of the ERG20 gene encoding farnesyl pyrophosphate synthase is shown in positions 1045-2103 of SEQ ID No.7. The nucleotide sequence of the ERG12 gene encoding mevalonate kinase is shown in positions 1045-2376 of SEQ ID No.8; the nucleotide sequence of the transcription activator UPC2 gene is shown in positions 1045-3786 of SEQ ID No.9; wherein, the SEQ ID No.5 is the nucleotide sequence of the tHMG1 gene recombination cassette; the SEQ ID No.6 is the nucleotide sequence of the IDI1 gene recombination cassette; the SEQ ID No.7 is the nucleotide sequence of the ERG20 gene recombination cassette; the SEQ ID No.8 is the nucleotide sequence of the ERG12 gene recombination cassette; and the SEQ ID No.9 is the nucleotide sequence of the UPC2 gene recombination cassette.
[0054] In some specific preferred embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in the recombinant yeast cells; the corresponding recombinant Saccharomyces cerevisiae cells are referred to as recombinant yeast cells B producing ganoderic acid DM in the present invention.
[0055] In some specific preferred embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase in recombinant yeast cells; in the present invention, the corresponding recombinant Saccharomyces cerevisiae cells are referred to as recombinant yeast cells C producing ganoderic acid DM.
[0056] In some specific preferred embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase and the ERG20 gene encoding farnesyl pyrophosphate synthase in recombinant yeast cells; in the present invention, the corresponding recombinant Saccharomyces cerevisiae cells are referred to as recombinant yeast cells D producing ganoderic acid DM.
[0057] In some specific preferred embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase and the ERG12 gene encoding mevalonate kinase in recombinant yeast cells; in the present invention, the corresponding recombinant Saccharomyces cerevisiae cells are referred to as recombinant yeast cells E producing ganoderic acid DM.
[0058] In some specific preferred embodiments of the present invention, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene in recombinant yeast cells; in the present invention, the corresponding recombinant Saccharomyces cerevisiae cells are referred to as recombinant yeast cells F producing ganoderic acid DM.
[0059] Based on the above, it is not difficult to understand that the above-mentioned recombinant yeast cells B to F producing ganoderic acid DM are obtained based on the recombinant yeast cell A producing ganoderic acid DM by optimizing the precursor synthesis pathway.
[0060] The research results show that the ganoderic acid DM-producing genetically engineered bacteria provided by the present invention can produce 118 mg / L of ganoderic acid DM after fermentation.
[0061] To implement the above embodiment, the present invention also provides a method for constructing the genetically engineered bacteria producing ganoderic acid DM described in the above embodiment of the present invention, which comprises:
[0062] Step (A), constructing a recombinant yeast cell A containing a CYP5150L8 gene encoding a CYP450 enzyme, a CYP7A1 gene encoding a 7α-hydroxylase, a HSD3B7 gene encoding a 3β-hydroxysteroid dehydrogenase, and a 7α-HSDH gene encoding a 7α-hydroxysteroid dehydrogenase;
[0063] Step (Z), optimizing the precursor synthesis pathway.
[0064] According to some embodiments of the present invention, step (A) comprises:
[0065] Step M, expressing the CYP5150L8 gene encoding the CYP450 enzyme and the CYP7A1 gene encoding the 7α-hydroxylase in yeast cells;
[0066] Step N, expressing the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase in yeast cells.
[0067] In some preferred embodiments of the present invention, the step (A) comprises constructing a recombinant yeast cell A (also referred to as genetically engineered bacteria A producing ganoderic acid DM in the present invention) containing the CYP5150L8 gene encoding a CYP450 enzyme, the CYP7A1 gene encoding a 7α-hydroxylase, the HSD3B7 gene encoding a 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding a 7α-hydroxysteroid dehydrogenase.
[0068] Among them, the nucleotide sequences of the CYP5150L8 gene encoding CYP450 enzyme, the CYP7A1 gene encoding 7α-hydroxylase, the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase are shown as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, and SEQ ID No.4, respectively.
[0069] In a specific embodiment of the present invention, the step (A) is achieved by constructing a plasmid for driving the expression of the target gene with a strong promoter, connecting the CYP5150L8 gene fragment from Ganoderma lucidum and the CYP7A1 gene fragment from Homo sapiens to plasmid pSP-GM2 to obtain plasmid pSP-GM2-CYP5150L8-CYP7A1, connecting the HSD3B7 gene fragment from Homo sapiens and the 7α-HSDH gene from Clostridium sardiniense to plasmid pRS425-pGM2 to obtain plasmid pRS425-pGM2-HSD3B7-7α-HSDH, and the nucleotide sequences of the CYP5150L8 gene, CYP7A1 gene, HSD3B7 gene, and 7α-HSDH gene are as shown in SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID As shown in No.4; plasmids pSP-GM2-CYP5150L8-CYP7A1 and pRS425-pGM2-HSD3B7-7α-HSDH were transformed into the original strain YS58 by lithium acetate transformation method to obtain recombinant yeast cell A.
[0070] According to some other embodiments of the present invention, the step (Z) comprises:
[0071] Step (B), overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in the recombinant yeast cell A to obtain the recombinant yeast cell B;
[0072] Alternatively, in step (C), the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell C;
[0073] Alternatively, in step (D), the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell D;
[0074] Alternatively, in step (E), the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase and the ERG12 gene encoding mevalonate kinase are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell E.
[0075] Alternatively, in step (F), the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene are overexpressed in the recombinant yeast cell to obtain the recombinant yeast cell F.
[0076] Furthermore, in step (B), the co-expression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase can be achieved by introducing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase into Saccharomyces cerevisiae.
[0077] The nucleotide sequence of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase of Saccharomyces cerevisiae is shown in positions 1045-2580 of SEQ ID No.5.
[0078] In a specific embodiment of the present invention, the overexpression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase is achieved by homologous recombination technology. Using the genome of Saccharomyces cerevisiae YS58 as a template, PCR amplification is performed to obtain a tHMG1 gene fragment, and the tHMG1 gene fragment is connected to the plasmid pRS414-pGM2 to obtain the plasmid pRS414-pGM2-tHMG1, wherein the nucleotide sequence of the tHMG1 gene is shown in positions 1045-2580 of SEQ ID No. 5; the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase is transferred into the strain obtained in step (A) in the form of a recombinant DNA fragment using a lithium acetate transformation method, so that the tHMG1 gene is integrated into a specific integration site, SEQ ID No. 5 has positions 1-60 as the upstream homology arm of the integration site, positions 61-1044 as the PGK1 promoter, positions 1045-2580 as the tHMG1 gene, positions 2581-2745 as the ADH1 terminator, positions 2746-3701 as the TRP screening gene, and positions 3702-3761 as the downstream homology arm of the integration site;
[0079] In step (C), the yeast cell is caused to simultaneously overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase by simultaneously introducing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase into Saccharomyces cerevisiae.
[0080] In a specific embodiment of the present invention, overexpression of the IDI1 gene encoding isopentenyl diphosphate δ-isomerase is achieved by homologous recombination technology. The YS58 genome of Saccharomyces cerevisiae is used as a template for PCR amplification to obtain an IDI1 gene fragment, and the IDI1 gene fragment is connected to a plasmid pRS414-pGM2 to obtain a plasmid pRS414-pGM2-IDI1, wherein the nucleotide sequence of the IDI1 gene is shown in positions 1045-1911 of SEQ ID No.6; the IDI1 gene encoding isopentenyl diphosphate delta-isomerase is transferred into the strain obtained in step (B) in the form of a recombinant DNA fragment using a lithium acetate transformation method, so that the IDI1 gene is integrated into a specific integration site, wherein positions 1-60 of SEQ ID No.6 are homologous arms upstream of the integration site, positions 61-1044 are PGK1 promoters, positions 1045-1911 are IDI1 genes, positions 1912-2076 are ADH1 terminators, positions 2077-3032 are TRP screening genes, and positions 3033-3092 are homologous arms downstream of the integration site.
[0081] In step (D), the simultaneous overexpression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthetase can be achieved by simultaneously introducing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthetase into Saccharomyces cerevisiae.
[0082] In a specific embodiment of the present invention, the overexpression of the ERG20 gene encoding farnesyl pyrophosphate synthase is achieved by homologous recombination technology. Using the genome of Saccharomyces cerevisiae YS58 as a template, PCR amplification is performed to obtain an ERG20 gene fragment, and the ERG20 gene fragment is connected to the plasmid pRS414-pGM2 to obtain a plasmid pRS414-pGM2-ERG20, wherein the nucleotide sequence of the ERG20 gene is shown in positions 1045-2103 of SEQ ID No.7; the ERG20 gene encoding farnesyl pyrophosphate synthase is transferred into the strain obtained in step (C) in the form of a recombinant DNA fragment using a lithium acetate transformation method, so that the ERG20 gene is integrated into a specific integration site, SEQ ID Positions 1-60 of No.7 are the upstream homologous arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-2103 are the ERG20 gene, positions 2104-2268 are the ADH1 terminator, positions 2269-3224 are the TRP screening gene, and positions 3225-3284 are the downstream homologous arms of the integration site.
[0083] In step (E), the simultaneous overexpression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase in the Saccharomyces cerevisiae can be achieved by simultaneously introducing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase into the Saccharomyces cerevisiae.
[0084] In a specific embodiment of the present invention, the overexpression of the ERG12 gene encoding mevalonate kinase is achieved by homologous recombination technology. Using the YS58 genome of Saccharomyces cerevisiae as a template, PCR amplification is performed to obtain the ERG12 gene fragment, and ERG12 Gene fragment ligated to plasmid p RS414 -p GM2 , and obtain the plasmid p RS414 -p GM2-ERG12 , The nucleotide sequence of the ERG12 gene is shown in positions 1045-2376 of SEQ ID No.8; the ERG12 gene encoding mevalonate kinase is transferred into the strain obtained in step (D) in the form of a recombinant DNA fragment using a lithium acetate transformation method, so that the ERG12 gene is integrated into a specific integration site, positions 1-60 of SEQ ID No.8 are the upstream homologous arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-2376 are the ERG12 gene, positions 2377-2541 are the ADH1 terminator, positions 2542-3497 are the TRP screening gene, and positions 3498-3557 are the downstream homologous arms of the integration site.
[0085] In step (F), the simultaneous overexpression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthetase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene in the Saccharomyces cerevisiae can be achieved by simultaneously introducing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthetase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene into the Saccharomyces cerevisiae.
[0086] In a specific embodiment of the present invention, overexpression of the endogenous transcription activator UPC2 gene is achieved by homologous recombination technology. The genome of Saccharomyces cerevisiae YS58 is used as a template for PCR amplification to obtain a UPC2 gene fragment, and the UPC2 gene fragment is connected to a plasmid pRS414-pGM2 to obtain a plasmid pRS414-pGM2-UPC2, wherein the nucleotide sequence of the UPC2 is shown in positions 1045-3786 of SEQ ID No.9; the endogenous transcription activator UPC2 gene is transferred into the strain obtained in step (E) in the form of a recombinant DNA fragment using a lithium acetate transformation method, so that the UPC2 gene is integrated into a specific integration site, wherein positions 1-60 of SEQ ID No.9 are homologous arms upstream of the integration site, positions 61-1044 are PGK1 promoters, positions 1045-3786 are UPC2 genes, positions 3787-3951 are ADH1 terminators, positions 3952-4907 are TRP screening genes, and positions 4908-4967 are homologous arms downstream of the integration site.
[0087] In some specific preferred embodiments of the present invention, the method for constructing a genetically engineered bacterium producing ganoderic acid DM comprising step (A) can be understood as a method for producing ganoderic acid DM in Saccharomyces cerevisiae, which is carried out according to the method in step (A) to construct a recombinant yeast cell A (also referred to as genetically engineered bacterium A producing ganoderic acid DM in the present invention) containing the CYP5150L8 gene encoding a CYP450 enzyme, the CYP7A1 gene encoding a 7α-hydroxylase, the HSD3B7 gene encoding a 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding a 7α-hydroxysteroid dehydrogenase, thereby achieving the production of ganoderic acid DM in Saccharomyces cerevisiae.
[0088] In some other specific preferred embodiments of the present invention, the above-mentioned method comprising step (A) and constructing a genetically engineered bacterium producing ganoderic acid DM can be understood as a method for producing ganoderic acid DM in cerevisiae, which firstly expresses the CYP5150L8 gene encoding CYP450 enzyme, the CYP7A1 gene encoding 7α-hydroxylase, the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase according to the method in step (A) to achieve the production of ganoderic acid DM in cerevisiae, and then performs transformation according to steps (B), (C), (D), (E) and (F) respectively on this basis to achieve the construction of a genetically engineered bacterium producing ganoderic acid DM and improve the yield of ganoderic acid DM in cerevisiae.
[0089] As can be seen from the above, the genetically engineered bacteria producing ganoderic acid DM provided by the present invention are firstly transformed in Saccharomyces cerevisiae in step (A) to obtain an initial genetically engineered bacteria A, and then further transformed in steps (B) and / or (C) and / or (D) and / or (E) and / or (F) based on the initial genetically engineered bacteria (A) to obtain: wherein, step (A) expresses the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase. ; step (B) while expressing the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase, overexpressing the tHMG1 gene encoding the hydroxymethylglutaryl-CoA reductase; step (C) while expressing the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase. In step (D), while expressing the CYP5150L8 gene encoding the CYP450 enzyme, the CYP7A1 gene encoding the 7α-hydroxylase, the HSD3B7 gene encoding the 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding the 7α-hydroxysteroid dehydrogenase, the tHMG1 gene encoding the hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding the isopentenyl diphosphate δ-isomerase, and the 7α-HSDH gene encoding the 7α-HSDH gene ... I1 gene and ERG20 gene encoding farnesyl pyrophosphate synthase; step (E) while expressing CYP5150L8 gene encoding CYP450 enzyme, CYP7A1 gene encoding 7α-hydroxylase, HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase, overexpressing tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, IDI1 gene encoding isopentenyl diphosphate δ-isomerase, ERG20 gene encoding farnesyl pyrophosphate synthase and ERG12 gene encoding mevalonate kinase in Saccharomyces cerevisiae;Step (F) while expressing the CYP5150L8 gene encoding CYP450 enzyme, the CYP7A1 gene encoding 7α-hydroxylase, the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase, overexpresses the tHMG1 gene encoding hydroxymethylglutaryl coenzyme A reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase, and the endogenous transcription activator UPC2 gene of Saccharomyces cerevisiae. The present invention increases the content of ganoderic acid DM in Saccharomyces cerevisiae and breaks through the limitation of the source of ganoderic acid DM. ;
[0090] Those skilled in the art should understand that the above-mentioned steps (A) to (B), (C), (D), (E) or (F) of constructing the genetically engineered bacteria producing ganoderic acid DM can also be understood as genetically modifying the host organism. Therefore, the genetically engineered bacteria producing ganoderic acid DM are also referred to as genetically modified yeast cells producing ganoderic acid DM in the present invention.
[0091] The application of the above-mentioned genetically engineered bacteria or the genetically engineered bacteria constructed by the above-mentioned method in the production of ganoderic acid DM involved in the present invention can be understood as a method for producing ganoderic acid DM using the above-mentioned genetically engineered bacteria or the genetically engineered bacteria constructed by the above-mentioned method, and can also be further understood as a method for preparing or producing ganoderic acid DM using the above-mentioned genetically engineered bacteria or the genetically engineered bacteria constructed by the above-mentioned method.
[0092] Based on the foregoing, it is not difficult to understand that the method for constructing the genetically engineered bacteria producing ganoderic acid DM provided by the present invention can also be understood as the application of the genetically engineered bacteria producing ganoderic acid DM described in the above embodiment of the present invention to produce ganoderic acid DM in Saccharomyces cerevisiae;
[0093] Alternatively, the genetically engineered bacteria producing ganoderic acid DM described in the embodiments of the present invention are used in the preparation or production of ganoderic acid DM.
[0094] In some embodiments of the present invention, the genetically engineered bacteria are inoculated into a fermentation medium for fermentation culture, and then the obtained fermentation culture fluid is separated and purified to obtain ganoderic acid DM.
[0095] Specifically, the genetically engineered bacteria are inoculated into a fermentation medium for fermentation culture, including inoculating the engineered bacteria provided by the present invention into the YNB nutrient-deficient medium, activating the culture by shaking a flask at 30°C and 200rpm to obtain a seed solution; then inoculating the seed solution into the YNB nutrient-deficient medium for shaking a flask at 30°C and 200rpm for 168h, and collecting the fermentation product.
[0096] In some specific embodiments of the present invention, the method for preparing or producing ganoderic acid DM using the above-mentioned genetically engineered bacteria or the genetically engineered bacteria constructed by the above-mentioned method comprises the following steps:
[0097] (1) Fermenting and culturing the recombinant bacteria described in the first aspect in a YNB nutrient-deficient medium and collecting the fermentation product.
[0098] In a specific embodiment of the present invention, this step is specifically as follows: inoculating the engineered bacteria into the YNB nutrient-deficient culture medium, activating it by shaking flask culture at 30°C and 200rpm to obtain seed liquid; then inoculating the seed liquid into the YNB nutrient-deficient culture medium and shaking flask culture at 30°C and 200rpm for 168h.
[0099] (2) The cells are broken and the product is extracted to obtain ganoderic acid DM.
[0100] In a specific embodiment of the present invention, this step specifically includes: placing the fermentation product in an equal volume of ethyl acetate, extracting at 30° C., 200 rpm for 2 hours to obtain the product.
[0101] In other specific embodiments of the present invention, the method for preparing or producing ganoderic acid DM using the above genetically engineered bacteria or the genetically engineered bacteria constructed by the above method comprises the following steps:
[0102] (1) Fermenting and culturing the engineered bacteria described in the first aspect in a YNB nutrient-deficient medium and collecting the fermentation product.
[0103] In a specific embodiment of the present invention, this step is specifically as follows: inoculating the engineered bacteria into the YNB nutrient-deficient culture medium, activating the culture by shaking a flask at 30°C and 200rpm to obtain a seed solution; then inoculating the seed solution into the YNB nutrient-deficient culture medium at 30°C and 200rpm for 168h of shaking a flask culture, and collecting the fermentation product.
[0104] (2) extracting the fermentation product by an extraction method to obtain ganoderic acid DM.
[0105] In a specific embodiment of the present invention, the step is specifically as follows: the collected bacteria are repeatedly frozen and thawed four times, and then ultrasonically disrupted, the disrupted bacterial suspension is placed in an ethyl acetate solution, oscillated and mixed, the organic phase solution is absorbed, and then rotary evaporated to obtain the product. The obtained product is dissolved in methanol and waited for detection.
[0106] III. Correlation analysis and detection methods
[0107] The cells were frozen and thawed four times, and then ultrasonically disrupted. The disrupted cell suspension was placed in an ethyl acetate solution, shaken and mixed, and the organic phase solution was absorbed and then rotary evaporated to obtain the product. The residue was redissolved in methanol, filtered with a 0.22 μm organic phase filter, and then detected by HPLC. The Agilent 1260 Infinity II HPLC system equipped with a diode array detector (DAD) was used to measure at 210 nm using an Agilent SB-C18 column (5 μm, 4.6 mm × 250 mm). Mobile phase A was 100% water, and mobile phase B contained methanol / acetic acid (100: 0.1 v / v). A linear gradient of 1 mL / min from 80% to 100% B was used within 30 minutes, and then eluted with 100% B for 10 minutes.
[0108] IV. EXAMPLES
[0109] The present invention is described in detail below through specific examples. The experimental methods described below, unless otherwise specified, are all routine laboratory methods. The experimental materials described below, unless otherwise specified, can all be obtained from commercial channels.
[0110] The culture medium used in the following examples is as follows, wherein the percentages are all weight percentages:
[0111] The final concentration of YPD medium is as follows: 1% yeast powder, 2% peptone, 2% glucose, 1.7% agar (for solid medium), the solvent is deionized water, and the pH value is natural. % means g / 100mL.
[0112] The final concentration of YNB-Ura / Leu fermentation medium is composed of: 0.17% amino-free yeast nitrogen source (Shanghai Yuanye Biotechnology Co., Ltd., S24483), 0.5% ammonium sulfate, 0.129% Dropout Supplement-Ura / Leu (Beijing Coolable Technology Co., Ltd., PM2270), 2% glucose, the solvent is deionized water, pH 6.0. The addition of DS amino acids is determined by the screening marker of the expression vector, and 1.7% agar is added to the solid culture medium on the basis of the above components. % represents g / 100mL.
[0113] The final concentration of YNB-Ura / Leu / Trp fermentation medium is composed of: 0.17% amino-free yeast nitrogen source (Shanghai Yuanye Biotechnology Co., Ltd., S24483), 0.5% ammonium sulfate, 0.12% Dropout Supplement-Ura / Leu / Trp (Beijing Coolable Technology Co., Ltd., PM2270), 2% glucose, the solvent is deionized water, pH 6.0. The addition of DS amino acids is determined by the screening marker of the expression vector, and 1.7% agar is added to the solid culture medium on the basis of the above components. % represents g / 100mL.
[0114] The sequences involved in the following examples were commissioned to be synthesized by Genewise, Inc., among which:
[0115] The nucleotide sequence of the CYP5150L8 gene encoding the CYP450 enzyme is SEQ ID No.1.
[0116] The nucleotide sequence of the CYP7A1 gene encoding 7α-hydroxylase is SEQ ID No.2.
[0117] The nucleotide sequence of the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase is SEQ ID No.3.
[0118] The nucleotide sequence of the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase is SEQ ID No.4.
[0119] The nucleotide sequence of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase is positions 1045-2580 of SEQ ID No.5.
[0120] The nucleotide sequence of the IDI1 gene encoding isopentenyl diphosphate δ-isomerase is positions 1045-1911 of SEQ ID No.6.
[0121] The nucleotide sequence of the ERG20 gene encoding farnesyl pyrophosphate synthase is positions 1045-2103 of SEQ ID No.7.
[0122] The nucleotide sequence of the ERG12 gene encoding mevalonate kinase is positions 1045-2376 of SEQ ID No.8.
[0123] The nucleotide sequence of the endogenous transcription activator UPC2 gene is 1045-3786 of SEQ ID No. 9. Example 1: Construction of CYP5150L8-CYP7A1-HSD3B7-7α-HSDH engineered bacteria and analysis of its ganoderic acid DM production
[0124] 1. Construction of CYP5150L8-CYP7A1-HSD3B7-7α-HSDH engineered bacteria
[0125] (1) Construction of pSP-GM2-CYP5150L8-CYP7A1 plasmid and pRS425-pGM2-HSD3B7-7α-HSDH plasmid
[0126] The CYP5150L8 gene encoding CYP450 enzymes, the CYP7A1 gene encoding 7α-hydroxylase, the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase were all from exogenous sources, so the genes were searched through the NCBI website and sent to Suzhou GeneWeizhi Company for direct gene synthesis. The CYP5150L8 and CYP7A1 gene fragments were ligated into plasmid pSP-GM2 (https: / / www.ad The HSD3B7 and 7α-HSDH gene fragments were ligated to the plasmid pRS425-pGM2 between the restriction sites BamHⅠ and SalⅠ, PacⅠ and NotⅠ, respectively, to obtain the expression vector pRS425-pGM2-HSD3B7-7α-HSDH.
[0127] The nucleotide sequence of the CYP5150L8 gene is shown in SEQ ID No.1; the nucleotide sequence of the CYP7A1 gene is shown in SEQ ID No.2; the nucleotide sequence of the HSD3B7 gene is shown in SEQ ID No.3; and the nucleotide sequence of the 7α-HSDH gene is shown in SEQ ID No.4.
[0128] (2) Construction of CYP5150L8-CYP7A1-HSD3B7-7α-HSDH engineered bacteria
[0129] The above-mentioned pSP-GM2-CYP5150L8-CYP7A1 plasmid and pRS425-pGM2-HSD3B7-7α-HSDH plasmid were introduced into the YS58 strain of Saccharomyces cerevisiae for screening and expression using the lithium acetate transformation method. The details are as follows:
[0130] The host bacteria was selected from Saccharomyces cerevisiae YS58 (strain collection number ST12300, purchased from Beijing Krisbo Biotechnology Co., Ltd.), and the yeast transformation used the classic yeast transformation kit (Beijing Coolbo Technology Co., Ltd., SK2400). YPD medium was activated twice and cultured to the logarithmic phase for the preparation of competent cells, and the cells were collected by freezing centrifugation, washed twice, and then suspended with 1 / 10 concentration of LiAc. Prepare the premix: 240μl PEG Solution (Beijing Coolbo Technology Co., Ltd., SL9510), 36μl LiAc Solution (Beijing Coolbo Technology Co., Ltd. YT0002), 10μl Carrier DNA (Beijing Coolbo Technology Co., Ltd., YT0003), 5μl plasmid (the above-mentioned pSP-GM2-CYP5150L8-CYP7A1 plasmid and pRS425-pGM2-HSD3B7-7α-HSDH plasmid), and supplemented with sterile water to a final volume of 360μl. The premix was injected into YS58 competent cells, incubated in a water bath at 30°C and 42°C for 30 minutes, centrifuged, resuspended in sterile water and spread on URA / LEU defective screening medium (Beijing Lanbost Biological Co., Ltd., PM2251), and cultured at 30°C for 2-4 days to screen positive transformants to obtain the genetically engineered bacteria CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell A).
[0131] 2. Analysis of recombinant yeast cell A products
[0132] (1) Cultivation of engineered bacteria
[0133] Obtaining seed solution: The original strain YS58 was inoculated into YPD medium, and the recombinant yeast cell A was inoculated into YNB-Ura / Leu nutrient-deficient medium, and cultured in a constant temperature shaker at 200 rpm and 30°C for 48 hours. After activation culture, the seed solution was obtained.
[0134] Fermentation culture: The YS58 seed solution obtained by activation culture was inoculated into the YPD medium, and the recombinant yeast cell A seed solution obtained by repeated activation twice was inoculated into the YNB-Ura / Leu nutrient-deficient medium. The strain YS58 was used as the control strain, and the fermentation culture was carried out at 30°C and 200rpm for 168 hours to obtain the YS58 fermentation product and the recombinant yeast cell A fermentation product.
[0135] (2) Extraction of bacterial products
[0136] The fermentation products of the above strains were centrifuged at 8000g for 5 minutes to collect the cells and washed twice with water. The collected cells were repeatedly frozen and thawed, and then ultrasonically disrupted (Kunshan Ultrasonic Instrument Co., Ltd. KQ-500DE China). The disrupted cell suspension was placed in an equal volume of ethyl acetate solution, oscillated and mixed, and the organic phase solution was absorbed and rotary evaporated to obtain the product. The obtained product was dissolved in methanol and tested in liquid phase.
[0137] (3) Product analysis
[0138] HPLC detection of ganoderic acid DM: The determination was performed at 210 nm using an Agilent SB-C18 column (5 μm, 4.6 mm × 250 mm) equipped with a diode array detector (DAD) on an Agilent 1260 Infinity II HPLC system. Mobile phase A was 100% water, and mobile phase B contained methanol / acetic acid (100:0.1 v / v). A linear gradient of 1 mL / min from 80% to 100% B was used in 30 minutes, followed by elution with 100% B for 10 minutes.
[0139] The standard substance was ganoderic acid DM standard substance (Shanghai Yuanye Biotechnology Co., Ltd., B25881).
[0140] The results are as follows Figure 2 As shown in the implementation results, after expressing the CYP5150L8 gene encoding CYP450 enzyme, the CYP7A1 gene encoding 7α-hydroxylase, the HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase, and the 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase in the YS58 strain, ganoderic acid DM was successfully heterologously synthesized in Saccharomyces cerevisiae.
[0141] Example 2: Effect of overexpression of tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in recombinant yeast cell A on the production of ganoderic acid DM
[0142] 1. Construction of engineered bacteria overexpressing tHMG1
[0143] (1) Construction of tHMG1 expression vector
[0144] The tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase comes from Saccharomyces cerevisiae YS58, so the tHMG1 gene fragment is obtained by PCR amplification using the Saccharomyces cerevisiae YS58 genome as a template. tHMG1 is connected between the restriction sites SacⅠ and NotⅠ of the plasmid pRS414-pGM2 to obtain the expression vector pRS414-pGM2-tHMG1. The nucleotide sequence of the tHMG1 gene is shown in positions 1045-2580 of SEQID No.5.
[0145] Table 1 Primers used in this example
[0146]
[0147] (2) Design of tHMG1 gene recombination cassette
[0148] The location of the integration site on its chromosome was found through the NCBI website, and the upstream homology arm was designed 60bp upstream and the downstream homology arm was designed 60bp downstream according to the specific location of the integration site sequence. The primers were sent to Suzhou GeneWeichi Company for synthesis, and the expression vector pRS414-pGM2-tHMG1 was used as a template for PCR amplification to obtain the gene fragment tHMG1 recombination cassette.
[0149] The nucleotide sequence of the gene fragment tHMG1 recombination cassette is SEQ ID No. 5. Among them, positions 1-60 are the upstream homology arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-2580 are the tHMG1 gene, positions 2581-2745 are the ADH1 terminator, positions 2746-3701 are the TRP screening gene, and positions 3702-3761 are the downstream homology arms of the integration site.
[0150] (3) Construction of engineered bacteria overexpressing tHMG1
[0151] The above tHMG1 recombination cassette gene fragment was introduced into recombinant yeast cell A for screening and expression using the lithium acetate transformation method. The details are as follows:
[0152] The host bacteria was selected as recombinant yeast cell A, and the yeast transformation used the classic yeast transformation kit (Beijing Coolable Technology Co., Ltd., SK2400). YNB-Ura / Leu medium was activated twice and cultured to the logarithmic phase for the preparation of competent cells. The bacteria were collected by freezing centrifugation, washed twice with water and suspended with 1 / 10 concentration of LiAc. Prepare the premix: 240μl PEGSolution (Beijing Coolable Technology Co., Ltd. SL9510), 36μl LiAc Solution (Beijing Coolable Technology Co., Ltd. YT0002), 10μl Carrier DNA (Beijing Coolable Technology Co., Ltd. YT0003), 5μl fragment (the above-mentioned tHMG1 gene recombination box), and add sterile water to a final volume of 360μl. The premix was injected into the engineering competent cells, and then incubated in a water bath at 30°C and 42°C for 30 minutes. After centrifugation, the cells were resuspended in sterile water and spread on Ura / Leu / Trp defective screening medium (PM2251 from Beijing Lanbost Biological Co., Ltd.), and cultured at 30°C for 2-4 days to screen positive transformants to obtain the genetically engineered bacteria tHMG1-CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell B).
[0153] 2. Effect of overexpression of tHMG1 gene on ganoderic acid DM production
[0154] (1) Cultivation of engineered bacteria
[0155] Obtaining seed solution: recombinant yeast cell A was inoculated into YNB-Ura / Leu nutrient-deficient medium, and recombinant yeast cell B was inoculated into Ura / Leu / Trp nutrient-deficient medium, and cultured in a constant temperature shaker at 200 rpm and 30°C for 48 hours. After activation culture, seed solution was obtained.
[0156] Fermentation culture: The recombinant yeast cell A seed solution obtained by activation culture was inoculated into the YNB-Ura / Leu nutrient-deficient medium, and the recombinant yeast cell B seed solution obtained by repeated activation twice was inoculated into the YNB-Ura / Leu / Trp nutrient-deficient medium. Recombinant yeast cell A was used as the control strain, and the fermentation culture was carried out at 30°C and 200rpm for 168 hours to obtain the fermentation products of recombinant yeast cell A and recombinant yeast cell B.
[0157] (2) Product extraction and analysis: the culture method is the same as that in Example 1.
[0158] (3) Product analysis: the culture method is the same as that in Example 1.
[0159] The results are as follows Figure 3 As shown, compared with recombinant yeast cell A, the ganoderic acid DM production of recombinant yeast cell B was increased to 1.6 mg / L.
[0160] Example 3: Effect of overexpression of tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and IDI1 gene encoding isopentenyl diphosphate δ-isomerase in recombinant yeast cell A engineering bacteria on ganoderic acid DM production 1. Construction of genetic engineering bacteria overexpressing tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and IDI1 gene encoding isopentenyl diphosphate δ-isomerase
[0161] (1) Construction of IDI1 expression vector
[0162] The IDI1 gene encoding isopentenyl diphosphate delta-isomerase comes from Saccharomyces cerevisiae YS58, so the Saccharomyces cerevisiae YS58 genome was used as a template for PCR amplification to obtain the IDI1 gene fragment. The IDI1 gene fragment was ligated between the restriction sites SacⅠ and NotⅠ of the plasmid pRS414-pGM2 to obtain the expression vector pRS414-pGM2-IDI1. The nucleotide sequence of the IDI1 gene is shown in positions 1045-1911 of SEQ ID No.6.
[0163] Table 2 Primers used in this example
[0164]
[0165] (2) Design of IDI1 gene recombination cassette
[0166] The location of the integration site on its chromosome was found through the NCBI website, and according to the specific location of the integration site sequence, the upstream homology arm was designed 60bp upstream and the downstream homology arm was designed 60bp downstream. The primers were sent to Suzhou GeneWeichi Company for synthesis, and the expression vector pRS414-pGM2-IDI1 was used as a template for PCR amplification to obtain the gene fragment IDI1 recombination cassette.
[0167] The nucleotide sequence of the gene fragment IDI1 recombination cassette is SEQ ID No. 6. Among them, positions 1-60 are the upstream homology arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-1911 are the IDI1 gene, positions 1912-2076 are the ADH1 terminator, positions 2077-3032 are the TRP screening gene, and positions 3033-3092 are the downstream homology arms of the integration site.
[0168] (3) Construction of engineered bacteria overexpressing IDI1
[0169] The IDI1 recombination cassette gene fragment was integrated into the recombinant yeast cell B engineering bacteria described in Example 2 by lithium acetate transformation method for screening and expression. The transformation method was the same as that in Example 2.
[0170] Based on the above operations, the genetically engineered bacteria tHMG1-IDI1-CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell C) was obtained.
[0171] 2. Effect of simultaneous overexpression of tHMG1 and IDI1 genes on ganoderic acid DM content
[0172] (1) Cultivation of engineered bacteria
[0173] The engineering bacteria were cultured in the same manner as in Example 2, and the recombinant yeast cell C was fermented and cultured, while the recombinant yeast cell B was used as a control.
[0174] (2) Extraction of bacterial products is the same as the culture method in Example 1.
[0175] (3) Product analysis: the culture method is the same as that in Example 1.
[0176] The results are as follows Figure 3As shown, compared with the recombinant yeast cell B, the ganoderic acid DM production in the recombinant yeast cell C reached 12.4 mg / L, indicating that the overexpression of the IDI1 gene encoding isopentenyl diphosphate δ-isomerase in Saccharomyces cerevisiae can effectively catalyze the synthesis of ganoderic acid DM.
[0177] Example 4: Effect of overexpression of tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and ERG20 gene encoding farnesyl pyrophosphate synthase in recombinant yeast cell A engineered bacteria on ganoderic acid DM production
[0178] 1. Construction of genetically engineered bacteria overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthase
[0179] (1) Construction of ERG20 expression vector
[0180] The ERG20 gene encoding farnesyl pyrophosphate synthase comes from Saccharomyces cerevisiae YS58, so the genome of Saccharomyces cerevisiae YS58 is used as a template for PCR amplification to obtain the ERG20 gene fragment. The ERG20 gene fragments are respectively connected between the restriction sites SacⅠ and NotⅠ of the plasmid pRS414-pGM2 to obtain the expression vector pRS414-pGM2-ERG20. The nucleotide sequence of the ERG20 gene is shown in positions 1045-2103 of SEQ ID No.7.
[0181] Table 3 Primers used in this example
[0182]
[0183] (2) Design of ERG20 gene recombination cassette
[0184] The location of the integration site on its chromosome was found through the NCBI website, and according to the specific location of the integration site sequence, the upstream homology arm was designed 60bp upstream and the downstream homology arm was designed 60bp downstream. The primers were sent to Suzhou GeneWeichi Company for synthesis, and the expression vector pRS414-pGM2-ERG20 was used as a template for PCR amplification to obtain the gene fragment ERG20 recombination cassette.
[0185] The nucleotide sequence of the gene fragment ERG20 recombination cassette is SEQ ID No. 7. Among them, positions 1-60 are the upstream homology arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-2103 are the ERG20 gene, positions 2104-2268 are the ADH1 terminator, positions 2269-3224 are the TRP screening gene, and positions 3225-3284 are the downstream homology arms of the integration site.
[0186] (3) Construction of ERG20-overexpressing engineered bacteria
[0187] The ERG20 recombination cassette gene fragment was integrated into the recombinant yeast cell C engineering bacteria described in Example 3 by using the lithium acetate transformation method for screening and expression; the transformation method was the same as that in Example 2.
[0188] Based on the above operations, the genetically engineered bacteria tHMG1-IDI1-ERG20-CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell D) was obtained.
[0189] 2. Effect of simultaneous overexpression of tHMG1, IDI1 and ERG20 genes on ganoderic acid DM content
[0190] (1) Cultivation of engineered bacteria
[0191] The engineering bacteria culture method was the same as that in Example 2, and the recombinant yeast cell D was fermented and cultured, and the recombinant yeast cell C was used as a control.
[0192] (2) Extraction of bacterial products is the same as the culture method in Example 1.
[0193] (3) Product analysis: the culture method is the same as that in Example 1.
[0194] The results are as follows Figure 3 As shown, compared with the engineered bacteria recombinant yeast cell C, the ganoderic acid DM production in the recombinant yeast cell D reached 31.8 mg / L, indicating that the overexpression of the ERG20 gene encoding farnesyl pyrophosphate synthase in Saccharomyces cerevisiae can more efficiently catalyze the synthesis of ganoderic acid DM.
[0195] Example 5: Effect of overexpression of the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase in the recombinant yeast cell A engineered bacterium on the DM production of ganoderic acid in the engineered bacterium 1. Construction of an engineered bacterium overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase
[0196] (1) Construction of ERG12 expression vector
[0197] The ERG12 gene encoding farnesyl pyrophosphate synthase comes from Saccharomyces cerevisiae YS58, so the genome of Saccharomyces cerevisiae YS58 is used as a template for PCR amplification to obtain the ERG12 gene fragment. The ERG12 gene fragments are respectively connected between the restriction sites SacⅠ and NotⅠ of the plasmid pRS414-pGM2 to obtain the expression vector pRS414-pGM2-ERG12. The nucleotide sequence of the ERG12 gene is shown in positions 1045-2376 of SEQ ID No.8.
[0198] Table 4 Primers used in this example
[0199]
[0200] (2) Design of ERG12 gene recombination cassette
[0201] The location of the integration site on its chromosome was found through the NCBI website, and the upstream homology arm was designed 60bp upstream and the downstream homology arm was designed 60bp downstream according to the specific location of the integration site sequence. The primers were sent to Suzhou GeneWeichi Company for synthesis, and PCR amplification was performed using the expression vector pRS414-pGM2-ERG12 as a template to obtain the gene fragment ERG12 recombination cassette.
[0202] The nucleotide sequence of the gene fragment ERG12 recombination cassette is SEQ ID No. 8. Among them, positions 1-60 are the upstream homology arms of the integration site, positions 61-1044 are the PGK1 promoter, positions 1045-2376 are the ERG12 gene, positions 2377-2541 are the ADH1 terminator, positions 2542-3497 are the TRP screening gene, and positions 3498-3557 are the downstream homology arms of the integration site.
[0203] (3) Construction of ERG12-overexpressing engineered bacteria
[0204] The ERG12 recombination cassette gene fragment was integrated into the recombinant yeast cell D engineering bacteria described in Example 4 for screening and expression using the lithium acetate transformation method. The transformation method was the same as that in Example 2.
[0205] Based on the above operations, the genetically engineered bacteria tHMG1-IDI1-ERG20-ERG12-CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell E) was obtained.
[0206] 2. Effect of simultaneous overexpression of tHMG1, IDI1, ERG20 and ERG12 genes on ganoderic acid DM production
[0207] (1) Cultivation of engineered bacteria
[0208] The same culture method as in Example 2 was used to ferment and culture the recombinant yeast cell E, and the recombinant yeast cell D was used as a control.
[0209] (2) Extraction of bacterial products is the same as in Example 1.
[0210] (3) Product analysis: the method is the same as that in Example 1.
[0211] The results are as follows Figure 3 As shown, compared with the recombinant yeast cell D, the ganoderic acid DM production in the recombinant yeast cell E reached 54.9 mg / L, indicating that the overexpression of the ERG12 gene encoding endogenous mevalonate kinase in Saccharomyces cerevisiae can more efficiently catalyze the synthesis of ganoderic acid DM.
[0212] Example 6: Effect of overexpression of tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, IDI1 gene encoding isopentenyl diphosphate δ-isomerase, ERG20 gene encoding farnesyl pyrophosphate synthase, ERG12 gene encoding mevalonate kinase and transcription activator UPC2 gene in recombinant yeast cell A engineered bacteria on the production of ganoderic acid DM
[0213] 1. Construction of genetically engineered bacteria that overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase, and the transcription activator UPC2
[0214] (1) Construction of UPC2 expression vector
[0215] The transcription activator UPC2 gene comes from Saccharomyces cerevisiae YS58, so the Saccharomyces cerevisiae YS58 genome was used as a template for PCR amplification to obtain the UPC2 gene fragment. The UPC2 gene fragment was ligated between the restriction sites SacⅠ and NotⅠ of the plasmid pRS414-pGM2 to obtain the expression vector pRS414-pGM2-UPC2. The nucleotide sequence of the UPC2 gene is shown in the 1045-3786th position of SEQ ID No.9.
[0216] Table 5 Primers used in this example
[0217]
[0218] Based on the above operations, the genetically engineered bacteria tHMG1-IDI1-ERG20-ERG12-UPC2-CYP5150L8-CYP7A1-HSD3B7-7α-HSDH (recombinant yeast cell F) was obtained.
[0219] 2. Effect of simultaneous overexpression of tHMG1, IDI1, ERG20, ERG12 and UPC2 genes on ganoderic acid DM production
[0220] (1) Cultivation of engineered bacteria
[0221] The engineering bacteria culture method was the same as that in Example 2, and the recombinant yeast cell F was fermented and cultured, and the recombinant yeast cell E was used as a control.
[0222] (2) Extraction of bacterial products is the same as the culture method in Example 1.
[0223] (3) Product analysis: the culture method is the same as that in Example 1.
[0224] The results are as follows Figure 3 As shown, compared with the recombinant yeast cell E, the ganoderic acid DM production in the recombinant yeast cell F reached 118 mg / L, indicating that the overexpression of the Saccharomyces cerevisiae transcription activator UPC2 gene activated the expression of MVA pathway genes and greatly increased the production of ganoderic acid DM.
[0225] It should be noted that the embodiments described above are only preferred embodiments of the present invention, which are used to explain the present invention and do not constitute any limitation to the present invention. The present invention has been described with reference to typical embodiments, but it should be understood that the words used therein are descriptive and explanatory words, rather than restrictive words. The present invention may be modified as specified within the scope of the claims of the present invention, and the present invention may be revised without departing from the scope and spirit of the present invention. Although the present invention described therein relates to specific methods, materials and embodiments, it does not mean that the present invention is limited to the specific examples disclosed therein. On the contrary, the present invention can be extended to all other methods and applications with the same functions.
Claims
1. A genetically engineered bacterium producing ganoderic acid DM, which is a recombinant yeast cell expressing exogenous CYP5150L8 gene encoding CYP450 enzyme, CYP7A1 gene encoding 7α-hydroxylase, HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase.
2. The genetically engineered bacterium according to claim 1, characterized in that: The CYP5150L8 gene includes a CYP5150L8 gene encoding a CYP450 enzyme derived from Ganoderma lucidum and subjected to codon optimization; preferably, the nucleotide sequence of the CYP5150L8 gene is as shown in SEQ ID NO.1; And / or, the CYP7A1 gene includes a CYP7A1 gene encoding 7α-hydroxylase derived from Homo sapiens and subjected to codon optimization; preferably, the nucleotide sequence of the CYP7A1 gene is shown in SEQ ID NO.2; And / or, the HSD3B7 gene includes a codon-optimized HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase derived from Homo sapiens; preferably, the nucleotide sequence of the HSD3B7 gene is shown in SEQ ID NO.3; And / or, the 7α-HSDH gene includes a codon-optimized 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase derived from Clostridium sardiniense; preferably, the nucleotide sequence of the 7α-HSDH gene is shown in SEQ ID NO.
4.
3. The genetically engineered bacterium according to claim 1 or 2, characterized in that: The expression method is plasmid expression or genome integration expression.
4. The genetically engineered bacterium according to any one of claims 1 to 3, characterized in that: The genetically engineered bacteria are genetically engineered bacteria that have undergone chassis modification; the chassis modification includes optimization of precursor synthesis pathways.
5. The genetically engineered bacterium according to claim 4, characterized in that: The optimization of the precursor synthesis pathway includes overexpressing one or more of the endogenous tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene in recombinant yeast cells.
6. The genetically engineered bacterium according to claim 5, characterized in that: The optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in recombinant yeast cells; Alternatively, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase in recombinant yeast cells; Alternatively, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthase in recombinant yeast cells; Alternatively, the optimization of the precursor synthesis pathway is to overexpress the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase in recombinant yeast cells; Alternatively, the precursor synthesis pathway is optimized by overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the transcription activator UPC2 gene in recombinant yeast cells.
7. The genetically engineered bacterium according to any one of claims 1 to 6, characterized in that: The yeast cell is selected from the group consisting of the following yeast cells: Yarrowia lipolytica, Rhodosporidium, Lipomyces, Lipomyces oleaginus, Rhodotorula glutinosus, Cryptococcus curvatus, Candida curvatus, Trichosporon fermentans, Candida lakafusi, Candida ferrugoides, Candida tropicalis, Candida utilis, Trichosporon dermestii and Saccharomyces cerevisiae, preferably Saccharomyces cerevisiae.
8. A method for constructing a genetically engineered bacterium according to any one of claims 1 to 7, comprising: The steps of constructing recombinant yeast cell A are as follows: using yeast cells as chassis strains to express exogenous CYP5150L8 gene encoding CYP450 enzyme, CYP7A1 gene encoding 7α-hydroxylase, HSD3B7 gene encoding 3β-hydroxysteroid dehydrogenase and 7α-HSDH gene encoding 7α-hydroxysteroid dehydrogenase to obtain recombinant yeast cell A.
9. The construction method according to claim 8, characterized in that: The construction method further comprises a step of optimizing the precursor synthesis pathway after the step of constructing the recombinant yeast cell A, which comprises: Overexpressing the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase in recombinant yeast cell A to obtain recombinant yeast cell B; Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase and the IDI1 gene encoding isopentenyl diphosphate δ-isomerase are overexpressed in the recombinant yeast cell A to obtain the recombinant yeast cell C; Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, and the ERG20 gene encoding farnesyl pyrophosphate synthase are overexpressed in the recombinant yeast cell A to obtain the recombinant yeast cell D; Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, and the ERG12 gene encoding mevalonate kinase are overexpressed in the recombinant yeast cell A to obtain the recombinant yeast cell E; Alternatively, the tHMG1 gene encoding hydroxymethylglutaryl-CoA reductase, the IDI1 gene encoding isopentenyl diphosphate δ-isomerase, the ERG20 gene encoding farnesyl pyrophosphate synthase, the ERG12 gene encoding mevalonate kinase and the endogenous transcription activator UPC2 gene are overexpressed in the recombinant yeast cell A to obtain the recombinant yeast cell F.
10. Use of the genetically engineered bacteria according to any one of claims 1 to 7 or the genetically engineered bacteria obtained by the construction method according to any one of claims 7 to 10 in the production of ganoderic acid DM; Preferably, the application includes inoculating the genetically engineered bacteria into a fermentation medium for fermentation culture, and then separating and purifying the obtained fermentation culture fluid to obtain ganoderic acid DM; Further preferably, the fermentation medium comprises one or more of YPD fermentation medium, YNB-Ura / Leu fermentation medium and YNB-Ura / Leu / Trp fermentation medium; And / or, further preferably, the fermentation culture temperature is 30°C; further preferably, the fermentation culture time is 168h.
Citation Information
Patent Citations
Cytochrome P450, nicotinamide adenine dinucleotide-cytochrome P450 reductase and application thereof
CN108866142A
Use of ganoderic acid a for Anti-depression
WO2015165382A1
Cited By
Recombinant saccharomyces cerevisiae for producing decaisopentenol as well as construction method and application of recombinant saccharomyces cerevisiae
CN121160500A
